Influenza A virus vaccine H3N2 - Novartis Vaccines

Drug Profile

Influenza A virus vaccine H3N2 - Novartis Vaccines

Latest Information Update: 25 May 2016

Price : $50

At a glance

  • Originator Novartis Vaccines
  • Developer Seqirus
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H3N2 subtype

Most Recent Events

  • 30 Sep 2014 Novartis Vaccines completes a phase I trial in Healthy volunteers in USA (NCT01855945)
  • 04 Jun 2013 Phase-I clinical trials in Influenza-A virus H3N2 subtype (prevention) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top